About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Nashville | 301 Studies

Clinical Trials Ovarian CancerNashville

Ovarian Cancer Clinical Trials in Nashville

Find 301 clinical trials for ovarian cancer near Nashville, Tennessee. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 21-40 of 301 trials

CompletedMirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersPICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive…NCT05041257·Duarte, California and 34 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedZoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both OvariesThis randomized phase II trial is studying zoledronate to see how well it works compared to observation in maintaining bone mineral density in patients who are undergoing surgery…NCT00305695·Scottsdale, Arizona and 94 others

TerminatedPaclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00023907·Phoenix, Arizona and 43 others

CompletedGefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal CancerRATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal…NCT00023699·Birmingham, Alabama and 52 others

TerminatedA Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersMulti-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous…NCT04025216·Phoenix, Arizona and 9 others

Active not recruitingA Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsThe main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid…NCT06607185·Birmingham, Alabama and 44 others

Active not recruitingSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCThis is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single…NCT04140526·Springdale, Arkansas and 36 others

TerminatedStudy to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerThis is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with…NCT02943317·Sarasota, Florida and 4 others

CompletedAZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasThis is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with…NCT03205176·Sarasota, Florida and 3 others

TerminatedChronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell TransplantRATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to…NCT00957736·Nashville, Tennessee and 2 others

CompletedA Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube CancerThe purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel.NCT03030287·Aurora, Colorado and 6 others

CompletedCOM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy…NCT03667716·Los Angeles, California and 10 others

RecruitingA Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerThis is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib…NCT04516447·Aurora, Colorado and 34 others

CompletedA Study of BIND-014 Given to Patients With Advanced or Metastatic CancerThe goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.NCT01300533·Scottsdale, Arizona and 5 others

RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.NCT05579366·Phoenix, Arizona and 66 others

CompletedQuality of Life in Survivors of Gynecologic CancerRATIONALE: Quality-of-life assessment in cancer survivors may help determine the long-term effects of having had gynecologic cancer and may help improve the quality of life for…NCT00003795·Birmingham, Alabama and 43 others

RecruitingA Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsThis is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1)…NCT05941507·Los Angeles, California and 7 others

RecruitingJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C MutationThis study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.NCT06386146·Denver, Colorado and 14 others

CompletedA Dose Finding Study of ZW49 in Patients With HER2-Positive CancersThis is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the…NCT03821233·Duarte, California and 15 others

TerminatedEvaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsThe objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic…NCT06714617·Denver, Colorado and 8 others

PreviousPage 2 of 16Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia